Olema Pharmaceuticals/$OLMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Ticker
$OLMA
Sector
Primary listing
Employees
117
Headquarters
Website
OLMA Metrics
BasicAdvanced
$568M
-
-$1.94
1.93
-
Price and volume
Market cap
$568M
Beta
1.93
52-week high
$12.47
52-week low
$2.86
Average daily volume
1.4M
Financial strength
Current ratio
11.088
Quick ratio
10.996
Long term debt to equity
1.043
Total debt to equity
1.377
Profitability
EBITDA (TTM)
-151.655
Management effectiveness
Return on assets (TTM)
-28.89%
Return on equity (TTM)
-49.72%
Valuation
Price to book
1.65
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-4.787
Free cash flow yield (TTM)
-20.89%
Free cash flow per share (TTM)
-1.73
Growth
Earnings per share change (TTM)
-6.46%
3-year earnings per share growth (CAGR)
-6.84%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
Bulls say / Bears say
Olema ended Q2 2025 with $361.9 million in cash, cash equivalents, and marketable securities, providing enough runway to fund late-stage trials for more than a year (GlobeNewswire)
In Q2 2025, Olema secured FDA agreement on a 90 mg once-daily dose of palazestrant for both the OPERA-01 and OPERA-02 Phase 3 trials, streamlining study design and supporting faster enrollment (GlobeNewswire)
On September 2, 2025, Olema entered a clinical trial agreement with Pfizer to test palazestrant in combination with atirmociclib in ER+/HER2- metastatic breast cancer, expanding its partnership network and combination therapy prospects (Investing.com)
Olema’s net loss widened to $43.8 million in Q2 2025 from $30.4 million a year earlier, driven by a one-time $10 million milestone payment and higher R&D expenses, increasing near-term cash burn (GlobeNewswire)
Although Olema held $361.9 million in cash, cash equivalents, and marketable securities, its cash position fell by $30.8 million quarter over quarter, pointing to significant spending and possible funding risks if clinical progress slows (GlobeNewswire)
Top-line results from the OPERA-01 Phase 3 trial of palazestrant are not expected until the second half of 2026, leaving a catalyst gap that could put pressure on the share price in the meantime (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Olema Pharmaceuticals stock?
Olema Pharmaceuticals (OLMA) has a market cap of $568M as of October 22, 2025.
What is the P/E ratio for Olema Pharmaceuticals stock?
The price to earnings (P/E) ratio for Olema Pharmaceuticals (OLMA) stock is 0 as of October 22, 2025.
Does Olema Pharmaceuticals stock pay dividends?
No, Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders as of October 22, 2025.
When is the next Olema Pharmaceuticals dividend payment date?
Olema Pharmaceuticals (OLMA) stock does not pay dividends to its shareholders.
What is the beta indicator for Olema Pharmaceuticals?
Olema Pharmaceuticals (OLMA) has a beta rating of 1.93. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.